H.C. Wainwright lowered the firm’s price target on Cocrystal Pharma (COCP) to $6 from $7 and keeps a Buy rating on the shares. The firm says CDI-988 demonstrated “further promise” via activity against emergent norovirus variants. It cites anticipated equity dilution for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCP:
- Cocrystal Pharma’s CDI-988 Featured at Military Symposium
- Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency
- Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza
- Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year
- Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988